A5086411679- Corporate Management and Leadership
- Advanced Breast Cancer Therapies
- Innovation, Technology, and Society
- PARP inhibition in cancer therapy
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Breast Lesions and Carcinomas
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Hearing Loss and Rehabilitation
- BRCA gene mutations in cancer
- Cancer, Hypoxia, and Metabolism
- Noise Effects and Management
- Colorectal Cancer Surgical Treatments
- Cancer Risks and Factors
- Cancer Immunotherapy and Biomarkers
- Sociology and Education Studies
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Hepatocellular Carcinoma Treatment and Prognosis
- Chemotherapy-related skin toxicity
RWTH Aachen University
2024-2025
Karlsruhe Institute of Technology
1996-2022
University Hospital Heidelberg
2014-2021
Heidelberg University
2014-2021
National Center for Tumor Diseases
2014-2021
German Cancer Research Center
2019-2021
Hôpital Saint Joseph
2009
Hôpital Ambroise-Paré
2009
Hôpital Beaujon
2009
Hôpital de la Timone
2009
Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring slides stained immunohistochemistry (IHC) for Ki-67 similar ER PgR. This method carries significant intra- inter-observer variability. Automatic with digital image analysis (qIHC) or assessment MKI67 gene expression RT-qPCR improve diagnostic accuracy. IHC visual was compared the nuclear tool (AperioTM) on core biopsies from a randomized clinical trial. Expression ESR1, PGR...
PurposeTreatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients advanced hormone receptor–positive, HER2-negative (HR HER2–) breast cancer (BC). However, real-world data on the implementation of usage, efficacy, toxicity have not yet been reported.MethodsThe PRAEGNANT registry was used to identify HR HER2– BC (n = 1136). The use chemotherapy, ET, everolimus CDK4/6i ET analyzed first-line, second-line, third-line therapy. Progression-free survival (PFS)...
CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to identify patients with advanced or metastatic breast Cancer for marker driven trials in Humans) is a prospective precision oncology program that uses genomics transcriptomics guide therapeutic decisions the management cancer. Herein, we report our single-center experience results on basis first 200 enrolled an ongoing trial.From June 2017 March 2019, who had either primary progressive disease, any number previous...
In a listening experiment with 24 participants, the localization accuracy of dynamic binaural synthesis employing individual and estimated head-related transfer functions (HRTFs) was compared to generic HRTFs in vertical horizontal direction. The featured five different HRTF estimation methods, high-frequency audiometry, proximal pointing, headphone equalization. While Knowles Electronics Mannikin for Acoustic Research (KEMAR) served as baseline, individually measured ones provided...
This study introduces the concept of activity-based acoustic situations in primary schools, which describe everyday sound environment classrooms. During a series noise measurements seven German differences parameters and subjective listening effort, as assessed by questionnaires, were investigated across situations. Classroom was analyzed for pressure level (SPL), A-weighted SPL, loudness, sharpness. The results showed statistically significant average loudness SPL between situations, with...
4584 Background: Liver cancer is the third leading cause of death globally, with most deaths occurring within one year diagnosis. The multi-kinase inhibitor sorafenib became first treatment approved by FDA and EMEA for HCC based on data from phase III Sorafenib Assessment Randomized Protocol (SHARP) trial, which demonstrated that 400mg bid increased overall survival (OS) vs placebo in patients advanced HCC. influence risk factors such as macroscopic vascular invasion (MVI) and/or...
Abstract It is well known that hearing in noisy situations more challenging than quiet environments. This holds true for adults and especially children. study employed a child-appropriate dual-task paradigm to investigate listening effort children aged six ten years young adults. The primary task involved word recognition, while the secondary evaluated digit recall. Additionally, subjective perception of was assessed using questionnaire. incorporated plausible sound reproduction examined...
4617 Background: Masitinib, a tyrosine kinase inhibitor targeting c-Kit, PDGFR, FGFR3 and affecting the FAK pathway, can enhance antiproliferative effects of gemcitabine (GEM) in human pancreatic cancer cells. This multicenter phase 2 study aimed to determine efficacy safety masitinib combination with GEM first-line treatment patients locally advanced (LAPC) or metastatic (MPC) cancer. Methods: Patients received oral (9 mg/kg/d) standard weekly infusion (1,000 mg/m2). Primary endpoint was...
Locoregional recurrence after neoadjuvant chemotherapy for primary breast cancer is associated with poor prognosis. It essential to identify patients at high risk of locoregional who may benefit from extended local therapy. Here, we examined the prediction accuracy and clinical applicability MD Anderson Prognostic Index (MDAPI).Prospective data 456 treated between 2003 2011 was analyzed. The Kaplan-Meier method used examine probabilities recurrence, distant metastases according individual...
4513 Background: Pts with metastatic pancreatic adenocarcinoma (MPA) have a poor prognosis no major survival improvement since the introduction of gemcitabine (Burris 1997). The LV5FU2-P regimen was reported as safe and active 9 months median overall (OS) in phase II trial (Taïeb 2002). This randomized multicenter III compared followed by arm A versus B to evaluate best sequence. Methods: measurable MPA, PS 0–2, non prior CT, were randomly assigned receive either (2-hour infusion LV 200...
3578 Background: The combination of high-dose irinotecan (260mg/m2) with LV5FU2 (FOLFIRI HD regimen) is feasible an acceptable safety profile and promising efficacy data (Ducreux et al. Oncology 2008;74:17-24). aim this phase II study was to evaluate the FOLFIRI plus bevacizumab (B) in patients (pts) selected on UGT1A1 polymorphism, which could be predictive toxicity efficacy. Methods: Pts *1/*1 (group 1) or *1/*28 2) genotypes previously untreated mCRC were treated 5 mg/kg D1, 260 mg/m² LV...
Today, public network providers perform usage-based charging of ATM services based on transmitted cells, allocated bandwidth, and connection time. Nevertheless, it is important being able to simplify the process by considering requested service category implied quality (QoS) that might be negotiated additionally. We present a framework its application representative which following aspects. First, we differentiate five categories: constant bit rate (CBR), real-time variable (rt-VBR),...